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oncogenic functions by targeting CDKN1A 
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Abstract 
Background: Genome-wide miRNA expression profile has identified microRNA (miR)-96 as one of upregulated miR-
NAs in clinical bladder cancer (BC) tissues compared to normal bladder tissues. The aim of this study was to confirm 
the expression pattern of miR-96 in BC tissues and to investigate its involvement in carcinogenesis.
Methods: Quantitative real-time PCR was performed to detect the expression levels of miR-96 in 60 BC and 40 nor-
mal control tissues. Bioinformatics prediction combined with luciferase reporter assay were used to verify whether the 
cyclin-dependent kinase inhibitor CDKN1A was a potential target gene of miR-96. Cell counting kit-8 and apoptosis 
assays were further performed to evaluate the effects of miR-96-CDKN1A axis on cell proliferation and apoptosis of BC 
cell lines.
Results: We validated that miR-96 was significantly increased in both human BC tissues and cell lines. According 
to the data of miRTarBase, CDKN1A might be a candidate target gene of miR-96. In addition, luciferase reporter and 
Western blot assays respectively demonstrated that miR-96 could bind to the putative seed region in CDKN1A mRNA 
3′UTR, and significantly reduce the expression level of CDKN1A protein. Moreover, we found that the inhibition of 
miR-96 expression remarkably decreased cell proliferation and promoted cell apoptosis of BC cell lines, which was 
consistent with the findings observed following the introduction of CDKN1A cDNA without 3′UTR restored miR-96.
Conclusions: Our data reveal that miR-96 may function as an onco-miRNA in BC. Upregulation of miR-96 may con-
tribute to aggressive malignancy partly through suppressing CDKN1A protein expression in BC cells.
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Background
Bladder cancer (BC) ranks the 9th most common malig-
nancy worldwide and is one of the costliest to clinically 
manage [1]. It represents a main cause of morbidity and 
mortality. Histologically, about 98 % of BC belong to epi-
thelial malignancies, with the vast majority being transi-
tional cell carcinomas (TCC), followed by squamous cell 
carcinoma (5 %) and adenocarcinoma (2 %) [2]. BC can 
be divided into two forms: low grade superficial tumors 
and high grade invasive tumors. Surgical resection is the 
primary and most effective treatment for patients with 
low grade superficial tumors [3]. However, there are still 
no efficient therapeutic strategies for high grade inva-
sive tumors. Although chemotherapy based on BCG may 
reduce recurrence in BC patients, more than 70  % will 
recur and approximately 30 % will eventually progress to 
muscle invasive disease or distant metastasis [4]. There-
fore, it is of great significance to identify novel and effec-
tive molecular markers for the early-stage diagnosis and 
for the evaluation of prognosis in patients with BC.
MicroRNAs (miRNAs) are small, endogenous and 
non-protein-coding RNAs that control gene expression 
post-transcriptionally by interacting with partially com-
plementary target sites in the 3′-untranslational region 
(UTR) of specific mRNA targets, either inducing their 
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degradation or impairing their translation [5]. Function-
ally, miRNAs are implicated in various cellular processes, 
including cell proliferation, differentiation, cell cycle and 
apoptosis [6]. Emerging data have shown the abnormal 
expression of miRNAs may be dramatically associated 
with several diseases, including cancers [7]. MiRNAs act 
as either oncogenes or tumor suppressors, and play cru-
cial roles in carcinogenesis, progression, and metastases. 
The tissue-specific nature of miRNA expression implies 
that different tumors would express specific miRNA sig-
natures [8]. Especially, previous study of Puerta-Gil et al. 
identified miR-143, miR-222, and miR-452 as tumor 
stratification and noninvasive diagnostic biomarkers for 
BC [9]; Majid et  al. [10] reported that miR-23b could 
function as a tumor suppressor that may confer a prolif-
erative advantage and promote bladder cancer cell migra-
tion and invasion; Wu et al. [11] also found that miR-99a 
could inhibit cell proliferation, migration and invasion by 
targeting fibroblast growth factor receptor 3 in BC. These 
findings suggest that it is of critical to identify the targets 
of miRNAs for understanding the function of miRNAs in 
cancer development and progression.
Genome-wide miRNA expression profile reported by 
Yoshino et  al. has identified miR-96 as one of upregu-
lated miRNAs in clinical BC tissues compared to normal 
bladder tissues [12]. Guo et  al. [13] identified that miR-
96 was downregulated in transitional cell carcinoma tis-
sues compared to normal bladder tissues, and regulated 
FOXO1-mediated cancer cell apoptosis, while Wang 
et al. [14] reported that miR-96 was expressed at higher 
levels in human bladder urothelial carcinomas compared 
to normal tissues, and found that miR-96 increased inva-
sion and differentiation of human bladder T24 cells and 
promoted cell growth. These converse findings prompt us 
to perform this study to confirm the expression pattern 
of miR-96 in BC tissues and to investigate its involvement 
in carcinogenesis.
Results
Upregulation of miR‑96 in BC tissues
Using quantitative real-time PCR, we found that the 
expression level of miR-96 was significantly increased in 
BC tissues compared with that in NBTC tissues as shown 
in Fig.  1a (BC vs. NBTC: 3.69  ±  0.91 vs. 1.86  ±  0.52, 
P  <  0.001), offering us an initial evidence that miR-96 
might be involved in the development of human BC.
miR‑96 negatively regulates the expression of CDKN1A 
in BC cells and tissues
We collected the candidate target genes of miR-96 from 
the experimentally validated microRNA-target inter-
actions database (miRTarBase, http://mirtarbase.mbc.
nctu.edu.tw/, Release 4.5), which has accumulated more 
than 50,000 miRNA–target interactions (MTIs). The 
data in miRTarBase are collected by manually survey-
ing pertinent literature after data mining of the text 
systematically to filter research articles related to func-
tional studies of miRNAs [15]. All MTIs in this database 
are validated experimentally by reporter assay, West-
ern blot, microarray and next-generation sequencing 
experiments. In the current study, only the MTIs which 
are validated experimentally by reporter assay, Western 
blot and quantitative real-time PCR were collected. As a 
result, a total of seven genes, including FOXO1, FOXO3, 
HTR1B, Mitf, CDKN1A, PRMT5 and KRAS, have been 
regarded as candidate target gene of miR-96 as shown 
in Table 1. According to our literature retrieval, miR-96-
FOXO1 axis has been indicated to play a crucial role in 
bladder carcinogenesis. Li et  al. [16] performed West-
ern blotting and dual-luciferase reporter assays to dem-
onstrate that miR-96 could bind to the putative seed 
region in FOXO3 mRNA 3′UTR, and could significantly 
decrease the expression of FOXO3 in non-small cell 
lung cancer cells. Jensen et al. [17] identified an element 
(A-element) within HTR1B mRNA that confers repres-
sion by miR-96. Xu et al. [18] performed target predic-
tion and in vitro functional studies showed that MITF, 
a transcription factor required for the establishment 
and maintenance of retinal pigmented epithelium, was 
a direct target of miR-96. Pal et  al. [19] also revealed 
that the decreased miR-96 expression could augment 
PRMT5 translation. Recent studies reported that the 
involvement of miR-96 in colorectal and pancreatic 
carcinogenesis might be related to its suppression on 
KRAS expression [20, 21]. In order to validate whether 
CDKN1A was a potential target of miR-96, luciferase 
reporter assay was performed. As shown in Fig.  1b, c, 
co-transfection with miR-96 inhibitor significantly 
increased the luciferase activity of the reporter contain-
ing the wild-type 3′-UTR (P < 0.05). Moreover, Western 
blot analysis also showed that the expression level of 
CDKN1A protein was significantly up-regulated in two 
human BC cell lines T24 and EJ transfected with miR-
96 inhibitor (both P  <  0.001, Fig.  1d). Importantly, the 
expression levels of CDKNIA mRNA in BC tissues were 
dramatically lower than those in NBTC tissues (BC vs. 
NBTC: 2.42 ± 1.05 vs. 3.71 ± 0.90, P < 0.001, Fig. 1e). 
The spearman correlation analysis also showed the neg-
ative correlation between miR-96 and CDKNIA mRNA 
expression levels in human BC tissues (rs  =  −0.34, 
P = 0.01, Fig. 1f ).
Taken together, these data demonstrated that miR-96 
could negatively regulate the expression of CDKN1A in 
both BC cells and tissues.
Page 3 of 9Wu et al. Cancer Cell Int  (2015) 15:107 
Fig. 1 miR-96 expression was upregulated in human bladder cancer (BC) tissues and could negatively regulate the expression of CDKN1A in 
both BC cells and tissues. a Using quantitative real-time PCR, we found that the expression level of miR-96 was significantly increased in BC tissues 
(n = 60) compared with that in NBTC tissues (n = 40; BC vs. NBTC: 3.69 ± 0.91 vs. 1.86 ± 0.52, P < 0.001); b the predicted CDKN1A 3′UTR-wild 
and CDKN1A 3′UTR-mut binding sequences in miR-96. c Co-transfection with miR-96 inhibitor significantly increased the luciferase activity of 
the reporter containing the wild-type 3′-UTR (*P < 0.05); d Western blot analysis also showed that the expression level of CDKN1A protein was 
significantly up-regulated in two human BC cell lines T24 and EJ transfected with miR-96 inhibitor (**P < 0.001); e using quantitative real-time PCR, 
we found that the expression level of CDKN1A mRNA was significantly decreased in BC tissues (n = 60) compared with that in NBTC tissues (n = 40; 
BC vs. NBTC: 2.42 ± 1.05 vs. 3.71 ± 0.90, P < 0.001); f Spearman correlation analysis showed the negative correlation between miR-96 and CDKNIA 
mRNA expression levels in human BC tissues (rs = −0.34, P = 0.01)
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Downregulation of miR‑96 inhibits cell proliferation of BC 
cells via regulating CDKN1A mRNA
To determine the effect of miR-96 on cell proliferation of 
BC cells, T24 and EJ cells were transfected with miR-96 
inhibitor and CCK8 assay was performed. As shown in 
Fig.  2a, b, the downregulation of miR-96 could remark-
ably inhibit the growth of both T24 and EJ cells (both 
P < 0.05). After that, recombinant CDKN1A without the 
3′UTR sequence (pcDNA3.1(+)-CDKN1A) was trans-
fected into two BC cells. Similar with the observations 
following the transfection of miR-96 inhibitor, the cell 
proliferation of both T24 and EJ cells transfected with 
pcDNA3.1(+)-CDKN1A was significantly suppressed 
(both P < 0.05, Fig. 2c, d).
Downregulation of miR‑96 promotes apoptosis of BC cells 
via regulating CDKN1A mRNA
To determine the effect of miR-96 on cell apoptosis, T24 
and EJ cells transfected with miR-96 inhibitor or NC 
were double-stained with Annexin V-FITC and PI and 
detected using flow cytometry. As shown in Fig. 3a, b, the 
downregulation of miR-96 could significantly promote 
apoptosis of both T24 and EJ cells (both P < 0.05), which 
was consistent with the observation after the transfec-
tion of the recombinant CDKN1A without the 3′UTR 
sequence (pcDNA3.1(+)-CDKN1A) (both P  <  0.05, 
Fig. 3c, d).
Discussion
Growing evidence show a direct link between miRNAs 
and human cancers. miRNAs often play a role in the 
control of carcinogenesis, cell proliferation and apop-
tosis of malignant cells by regulating the expression of 
the corresponding target genes. In the current study, we 
confirmed the upregulation of miR-96 in human BC tis-
sues, which was in line with the previous genome-wide 
miRNA expression profile reported by Yoshino et al. [12]. 
Table 1 Candidate target genes for  miR-96 according 
to the data of miRTarBase
LRA luciferase reporter assay, WB Western blot, IHC immunohistochemistry, NB 
northern blot
miRTarBase ID miRNA Target  
gene
Experiments
MIRT001087 hsa-miR-96 FOXO1 QPCR//LRA//WB//IHC//NB
MIRT002447 hsa-miR-96 HTR1B LRA
MIRT003144 hsa-miR-96 Mitf IHC//Microarray//qPCR//WB
MIRT003414 hsa-miR-96 CDKN1A LRA//Microarray//qPCR//WB
MIRT004352 hsa-miR-96 PRMT5 WB
MIRT005450 hsa-miR-96 FOXO3 LRA//qPCR//WB
MIRT005553 hsa-miR-96 KRAS IHC//NB//WB//LRA
Fig. 2 Downregulation of miR-96 inhibits cell proliferation of bladder cancer (BC) cells via regulating CDKN1A mRNA. a, b Downregulation of 
miR-96 could remarkably inhibit the growth of both T24 and EJ cells (both P < 0.05). c, d Transfection with pcDNA3.1(+)-CDKN1A significantly sup-
pressed cell proliferation of both T24 and EJ cells (both P < 0.05)
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In addition, bioinformatics prediction, combined with 
luciferase reporter and Western blot assays, identified 
CDKN1A as a potential target of miR-96, which could 
negative regulate the expression level of CDKN1A in 
both BC cells and tissues. Moreover, we found that the 
inhibition of miR-96 expression remarkably decreased 
cell proliferation and promoted cell apoptosis of BC cell 
lines, consisting with the findings observed following the 
introduction of CDKN1A cDNA without 3′UTR restored 
miR-96.
MiR-96, together with miR-182 and miR-183, belongs 
to the miR-183 family, which is located proximally on 
Fig. 3 Downregulation of miR-96 promotes apoptosis of bladder cancer (BC) cells via regulating CDKN1A mRNA. a, b Downregulation of miR-96 
could significantly promote apoptosis of both T24 and EJ cells (both P < 0.05); c, d transfection with pcDNA3.1(+)-CDKN1A significantly promoted 
apoptosis of both T24 and EJ cells (both P < 0.05)
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human chromosome 7, a region containing several onco-
genes and commonly amplified in cancers [17]. MiR-96, 
miR-182 and miR-183 share the same transcription start 
site (chr7: 129207158), suggesting that these miRNAs 
may be coordinately expressed and function together 
during carcinogenesis [18]. Recent studies showed that 
miR-96 was frequently increased in several human can-
cers. MiR-96 has been reported to exert an oncogenic 
effect in non-small cell lung cancer, esophageal can-
cer, breast cancer, hepatocellular carcinoma, and pros-
tate cancer, respectively by inhibiting the expression of 
FOXO3, RECK, FOXO3a and FOXO1 [16, 20–23]. On 
the other hand, miR-96 has been reported to function 
as a tumor suppressor in several cancers. For instance, 
miR-96 directly targeted the GTPase Kras (KRAS) onco-
gene in pancreatic cancer cells and ectopic expression of 
miR-96 through a synthetic miRNA precursor inhibited 
KRAS, dampened Akt signaling, and triggered apoptosis 
in cells [24, 25]. Regarding to BC, the conflict results on 
the expression patterns of miR-96 in human BC tissues 
have been reported by different research groups [13, 14]. 
Liu et  al. [26] also indicated that miR-183/96/182 clus-
ter might play oncogenic roles in BC. Similarly, we here 
found that the upregulation of miR-96 could enhance 
cellular proliferation and inhibit apoptosis of BC cells, 
implying that miR-96 might contribute to the carcino-
genesis and aggressive progression of BC.
In addition, we validated that CDKN1A (p21), which is 
an important inhibitor of the cell-cycle, regulator of the 
DNA damage response and effector of the tumor sup-
pressor p53 [27], was a potential target gene of miR-96 
in BC cells. As a major player in mammalian cell cycle 
progression, CDKN1A inhibits cyclin/cdk2 complexes 
and plays a crucial role in mediating growth arrest when 
cells are exposed to DNA damaging agents, implying its 
tumor suppressive role [28]. Several factors, including 
Ap2, BRCA1, C/EBPa, E2F-1/E2F-3, Sp1/Sp3, Smads and 
STAT, activate the transcription of CDKN1A [29]. Moreo-
ver, CDKN1A is also involved in terminal differentiation, 
replicative senescence and protection from p53-depend-
ent and -independent apoptosis [30]. Cazier et  al. [31] 
performed the whole-genome sequencing of BC revealed 
somatic CDKN1A mutations and clinicopathological 
associations with mutation burden. Liu et  al. [32] also 
found that TP53/CDKN1A double-mutant BC cells had 
a unique dependence on Chk1 activity for the G2-M cell-
cycle checkpoint in response to chemotherapy-induced 
DNA damage. CDKN1A could be regulated by several 
miRNAs in many cancers, including miR-519d, miR-
375, miR-31 and miR-663 [33–35]. In the current study, 
we found that miR-96 negatively regulated CDKN1A 
expression, and downregulation of miR-96 inhibited cell 
proliferation and promoted apoptosis in BC cells by tar-
geting CDKN1A.
In conclusion, our data reveal that miR-96 may func-
tion as an onco-miRNA in BC. Upregulation of miR-96 
may contribute to aggressive malignancy partly through 
suppressing CDKN1A protein expression in BC cells.
Methods
Ethics, consent and permissions
This work was approved by the Research Ethics Commit-
tee of Huai’an Hospital Affiliated of Xuzhou Medical Col-
lege, Huai’an Second People’s Hospital and Huai’an First 
People’s Hospital, Nanjing Medical University. Written 
informed consent was obtained from all of the patients. 
All specimens were handled and made anonymous 
according to the ethical and legal standards.
Consent to publish
We have obtained consent to publish from the partici-
pant (or legal parent or guardian for children) to report 
individual patient data.
Patients and tissue samples
Sixty TCC samples included 40 non muscle-invasive TCC 
samples which was collected by transurethral resection of 
bladder tumor and 20 muscle-invasive TCC tissue which 
was collected by radical cystectomy. Histological identifi-
cation of TCC was evaluated based on the World Health 
Organization criteria. The clinicopathological features 
of 60 patients with TCC were summarized in Table 2. In 
addition, 40 age-matched patients undergoing suprapu-
bic transvesical prostatectomy, lithocystotomy and cys-
tostomy for non-malignant diseases were collected for 
NBTC controls.
Cell culture
Two human bladder cancer cell lines, T24 and EJ, were 
purchased from the Type Culture Collection of the Chi-
nese Academy of Sciences (Shanghai, China) and cul-
tured in RPMI-1640 medium supplemented with 10  % 
fetal bovine serum (FBS) (Gibco, Grand Island, NY, USA) 
under a humidified air atmosphere of 5 % CO2 at 37 °C.
Cell transfection
A specific miR-96-5p inhibitor (sequence: 5′-AGC AAA 
AAU GUG CUA GUG CCA AA-3′, Shanghai GeneP-
harma Co. Ltd, Shanghai, China) and a negative con-
trol (NC, sequence: 5′-CAG UAC UUU UGU GUA 
GUA CAA-3′, Shanghai GenePharma Co. Ltd, Shang-
hai, China) were commercially purchased. Two human 
BC cell lines T24 and EJ were both plated at a den-
sity of 1.8  ×  105 cells/well in six-well plates. Transient 
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transfection was conducted using Lipofectamine™ 2000 
(Invitrogen, Carlsbad, CA, USA) following the manufac-
turer’s instructions which the cells reached ~60 % conflu-
ence. Forty-eight hours after transfection, the cells were 
harvested for further experiments.
RNA extraction and quantitative real‑time PCR
To detect the expression levels of miR-96 and CDKN1 
mRNA in TCC and NBTC tissues, and two human BC 
cell lines, total RNAs were extracted by Trizol reagent 
(Invitrogen, Carlsbad, CA, USA), and 1  μg of RNA was 
reversely transcripted. For miR-96, quantitative real-
time PCR was performed using a high-specificity miR-96 
Detection Kit (Stratagene Corp., La Jolla, CA, USA) in 
conjunction with an ABI 7500 thermal cycler, according 
to the manufacturer’s instruction. For CDKN1 mRNA, 
the PCR primer was: 5′-CAG AGG AGG CGC CAA 
GAC AG-3′ (forward) and 5′-CCT GAC GGC GGA 
AAA CGC-3′ (reverse). The RT-PCR kit (BD Biosciences, 
NJ, USA) was used in conjunction with an ABI 7500 ther-
mal cycler following the manufacturer’s protocol. U6 and 
GAPDH were used internal controls for the expression of 
miR-96 and CDKN1 mRNA, respectively. Relative miR-
96 and CDKN1 mRNA expression levels were calculated 
using the comparative threshold cycle (Ct) method [36].
Western blot analysis
To detect the expression levels of CDKN1A protein in 
human BC cell lines T24 and EJ transfected with miR-
96 inhibitor or NC, the Western blot analysis was per-
formed according to the previous studies [37, 38]. In 
brief, total proteins of transfected cells were extracted 
using RIPA buffer containing phenylmethanesulfo-
nyl fluoride (PMSF) and were quantified by a BCA kit 
(Thermo, Waltham, MA, USA). Proteins were separated 
by sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred to polyvinylidene 
difluoride (PVDF) membranes. The membranes were 
incubated overnight at 4  °C with diluted primary anti-
bodies (mouse anti-human CDKN1A antibody, 1:100, 
Cat. #AM2134b, Abgent Inc., San Diego, CA, USA; or 
mouse anti-human GAPDH, 1:100, Cat. #AM1020b, 
Abgent Inc., San Diego, CA, USA). Following extensive 
washing with Tris-buffered saline containing Tween 20 
(TBST), the secondary antibodies were incubated at 
room temperature for 1 h (HRP labeled goat anti-mouse 
IgG, 1:1000, Sangon Biotech, Shanghai, China) for 
1  h, and the membranes were detected by ECL system 
(Pierce, Rockford, IL, USA).
Luciferase reporter assay
To demonstrate whether CDKN1A mRNA was a target 
of miR-96, the luciferase reporter assay was performed 
according to the previous studies [37, 38]. In brief, the 
human CDKN1A mRNA fragments containing putative 
seed regions for miR-96 were amplified by PCR using 
the following primers: sense 5′-TTC TTC TAG AGG 
AAG CCC TAA TCC-3′ and antisense 5′-TCC CTT CTA 
GAA AGA TCT ACT CCC C-3′. The PCR product was 
inserted into psiCHECK2 luciferase miRNA expression 
reporter vector (Promega, Madison, WI, USA). Muta-
tion experiment was performed using a fast mutation kit 
(NEB, Ipswich, Canada). Two human BC cell lines T24 
and EJ were cultured in 24-well plate for 24  h and co-
transfected with 150 nM of miR-96 inhibitor or NC and 
WT or Mut 3′-UTR of CDKN1A using Lipofectamine 
2000. After that, transfected cells were collected, and 
the relative luciferase activity was assayed using Dual-
Luciferase Reporter Assay System (Promega, Wiscon-
sin, WI, USA). The results were normalized with Renilla 
luciferase. Each reporter plasmid was transfected at least 
three times (on different days) and each sample was 
assayed in triplicate.
Cell counting kit‑8 assay
Cell counting kit-8 (CCK8) assay was performed to 
observe the cell proliferation of human BC cell lines 
T24 and EJ transfected with miR-96 inhibitor and NC 
using CCK8 solution (Dojindo, Gaithersburg, MD, USA) 
Table 2 Clinicopathological features of  60 patients 
with bladder cancer
Clinicopathological features Case Percent (%)
Age (years)
 ≤50 40 66.7
 >50 20 33.3
Gender
 Male 45 75.0
 Female 15 25.0
Growth pattern
 Papillary 40 66.7
 Non-papillary 20 33.3
Pathological stage
 pTa 28 46.7
 pT1 15 25.0
 pT2 10 16.7
 pT3 5 8.3
 pT4 2 3.3
Tumor grade
 G1 15 25.0
 G2 35 58.3
 G3 10 16.7
Lymph node metastasis
 Negative 40 66.7
 Positive 20 33.3
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according to the manufacturer’s protocol. Optical density 
was measured at 450 nm using a microplate reader.
Apoptosis assay
Apoptosis assay was performed to observe the cell apop-
tosis of human BC cell lines T24 and EJ transfected with 
miR-96 inhibitor and NC using Annexin V-FITC Apopto-
sis Detection Kit I (BestBio, Shanghai, China) according 
to the manufacturer’s protocol. The cells were analyzed 
using flow cytometry (FACSCalibur, Beckman Coulter, 
Miami, FL, USA).
Statistical analysis
Statistical analysis in the current study was performed by 
the software of SPSS version 13.0 for Windows (SPSS Inc, 
IL, USA). All the experiments were done in triplicate and 
continuous variables were expressed as Mean ± SD. Stu-
dent’s t test and one-way analysis of variance (ANOVA) 
were used to determine the statistical significance of dif-
ferences, which were considered statistically significant 
when p was less than 0.05.
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